Stone Run Capital’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $5.48M | Sell |
70,400
-50
| -0.1% | -$3.91K | 2.16% | 20 |
|
|
2025
Q2 | $5.51M | Sell |
70,450
-150
| -0.2% | -$11.2K | 2.2% | 20 |
|
|
2025
Q1 | $5.12M | Sell |
70,600
-6,250
| -8% | -$447K | 2.16% | 22 |
|
|
2024
Q4 | $5.69M | Sell |
76,850
-6,325
| -8% | -$443K | 2.24% | 22 |
|
|
2024
Q3 | $5.49M | Buy |
83,175
+3,850
| +5% | +$280K | 2.04% | 26 |
|
|
2024
Q2 | $7.33M | Buy |
79,325
+1,475
| +2% | +$131K | 2.93% | 11 |
|
|
2024
Q1 | $7.44M | Sell |
77,850
-1,950
| -2% | -$164K | 2.84% | 12 |
|
|
2023
Q4 | $6.08M | Buy |
79,800
+4,600
| +6% | +$320K | 2.61% | 20 |
|
|
2023
Q3 | $5.21M | Buy |
75,200
+175
| +0.2% | +$14.1K | 2.55% | 20 |
|
|
2023
Q2 | $7.08M | Hold |
75,025
| – | – | 3.14% | 14 |
|
|
2023
Q1 | $6.21M | Hold |
75,025
| – | – | 2.97% | 15 |
|
|
2022
Q4 | $5.6M | Sell |
75,025
-1,600
| -2% | -$123K | 2.83% | 16 |
|
|
2022
Q3 | $6.33M | Sell |
76,625
-1,500
| -2% | -$144K | 3.41% | 12 |
|
|
2022
Q2 | $7.43M | Sell |
78,125
-12,100
| -13% | -$1.25M | 3.74% | 10 |
|
|
2022
Q1 | $10.6M | Buy |
90,225
+1,000
| +1% | +$112K | 3.93% | 3 |
|
|
2021
Q4 | $11.6M | Sell |
89,225
-3,660
| -4% | -$427K | 3.73% | 6 |
|
|
2021
Q3 | $10.5M | Sell |
92,885
-140
| -0.2% | -$16K | 3.61% | 7 |
|
|
2021
Q2 | $9.63M | Buy |
93,025
+500
| +0.5% | +$47.1K | 3.4% | 8 |
|
|
2021
Q1 | $7.74M | Sell |
92,525
-700
| -0.8% | -$59.2K | 2.96% | 12 |
|
|
2020
Q4 | $8.51M | Hold |
93,225
| – | – | 3.38% | 9 |
|
|
2020
Q3 | $7.44M | Sell |
93,225
-600
| -0.6% | -$46.8K | 3.4% | 7 |
|
|
2020
Q2 | $6.48M | Sell |
93,825
-5,700
| -6% | -$405K | 3.21% | 12 |
|
|
2020
Q1 | $6.26M | Sell |
99,525
-12,450
| -11% | -$898K | 3.59% | 5 |
|
|
2019
Q4 | $8.71M | Sell |
111,975
-4,275
| -4% | -$334K | 3.87% | 5 |
|
|
2019
Q3 | $8.52M | Sell |
116,250
-600
| -0.5% | -$42.1K | 4.06% | 3 |
|
|
2019
Q2 | $7.2M | Hold |
116,850
| – | – | 3.29% | 7 |
|
|
2019
Q1 | $7.45M | Hold |
116,850
| – | – | 3.67% | 5 |
|
|
2018
Q4 | $5.97M | Sell |
116,850
-24,000
| -17% | -$1.21M | 3.72% | 6 |
|
|
2018
Q3 | $8.17M | Hold |
140,850
| – | – | 3.75% | 3 |
|
|
2018
Q2 | $6.83M | Hold |
140,850
| – | – | 3.6% | 4 |
|
|
2018
Q1 | $6.55M | Sell |
140,850
-4,500
| -3% | -$195K | 3.44% | 5 |
|
|
2017
Q4 | $5.46M | Sell |
145,350
-8,700
| -6% | -$319K | 2.81% | 11 |
|
|
2017
Q3 | $5.61M | Hold |
154,050
| – | – | 2.89% | 11 |
|
|
2017
Q2 | $6.07M | Buy |
154,050
+300
| +0.2% | +$10.9K | 3.35% | 5 |
|
|
2017
Q1 | $4.82M | Sell |
153,750
-7,800
| -5% | -$244K | 2.9% | 11 |
|
|
2016
Q4 | $5.05M | Buy |
161,550
+24,150
| +18% | +$782K | 3.28% | 8 |
|
|
2016
Q3 | $5.52M | Hold |
137,400
| – | – | 3.44% | 5 |
|
|
2016
Q2 | $4.57M | Sell |
137,400
-10,500
| -7% | -$359K | 2.98% | 9 |
|
|
2016
Q1 | $4.35M | Buy |
147,900
+4,500
| +3% | +$124K | 2.8% | 9 |
|
|
2015
Q4 | $3.77M | Sell |
143,400
-12,000
| -8% | -$312K | 2.62% | 9 |
|
|
2015
Q3 | $3.68M | Sell |
155,400
-9,150
| -6% | -$221K | 2.93% | 9 |
|
|
2015
Q2 | $3.91M | Sell |
164,550
-13,500
| -8% | -$305K | 2.56% | 12 |
|
|
2015
Q1 | $4.23M | Sell |
178,050
-21,300
| -11% | -$478K | 2.72% | 9 |
|
|
2014
Q4 | $3.39M | Hold |
199,350
| – | – | 2.33% | 10 |
|
|
2014
Q3 | $3.39M | Sell |
199,350
-150
| -0.1% | -$2.37K | 2.4% | 10 |
|
|
2014
Q2 | $2.85M | Sell |
199,500
-6,000
| -3% | -$81.3K | 1.87% | 18 |
|
|
2014
Q1 | $2.54M | Buy |
205,500
+106,500
| +108% | +$1.23M | 1.84% | 21 |
|
|
2013
Q4 | $1.08M | Buy |
+99,000
| New | +$1.12M | 0.76% | 46 |
|
Other funds holding EW
Stone Run Capital's EW Position: Q3 2025 in Review
Stone Run Capital reduced its Edwards Lifesciences (EW) stake by 0.07% in Q3 2025, selling an estimated $3.91K and leaving 70,400 shares worth $5.48M. The position accounts for 2.16% of the portfolio, ranked #20.
Stone Run Capital first reported a position in EW in Q4 2013 and has held it in 48 quarters since. The position peaked at $11.6M in Q4 2021. 1,253 funds tracked by Wall St. Rank hold EW as of Q3 2025.
- Stone Run Capital held 70,400 shares of Edwards Lifesciences worth $5.48M as of Q3 2025.
- Stone Run Capital sold 50 Edwards Lifesciences shares in Q3 2025, an estimated $3.91K.
- Edwards Lifesciences made up 2.16% of Stone Run Capital's portfolio in Q3 2025, its #20 holding.
- Stone Run Capital first reported a position in Edwards Lifesciences in Q4 2013 and has held it in 48 quarters since.
- Stone Run Capital's Edwards Lifesciences position peaked at $11.6M in Q4 2021.
- 1,253 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.
Based on Stone Run Capital's 13F filing for Q3 2025, filed 14 Nov 2025.